Pharmacogenetics in Africa, an opportunity for appropriate drug dosage regimens: on the road to personalized healthcare

CPT: Pharmacometrics and Systems Pharmacology

Volumn 2, Issue 5, 2013, Pages

  Masimirembwa, C ^a   Hasler, J A ^a  

^a African Institute of Biomedical Science and Technology   (Zimbabwe)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ACENOCOUMAROL; ANTIDEPRESSANT AGENT; ARTEMISININ; ATAZANAVIR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLOROQUINE; CODEINE; CYCLOPHOSPHAMIDE; DEXTROMETHORPHAN; DIAZEPAM; EFAVIRENZ; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISONIAZID; LOSARTAN; NEVIRAPINE; OMEPRAZOLE; PRIMAQUINE; PROGUANIL; QUININE; RIFAMPICIN; TICAGRELOR; TOLBUTAMIDE; WARFARIN; XENOBIOTIC AGENT;

AFRICA; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; GENETIC VARIABILITY; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

EID: 84881191679     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2013.17     Document Type: Review

References (10)

1. Campbell, M.C. & Tishkoff, S.A. African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Annu. Rev. Genomics Hum. Genet. 9, 403-433 (2008).
2. Meyer, U.A. Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nat. Rev. Genet. 5, 669-676 (2004).
3. Azuma, J. et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur. J. Clin. Pharmacol. (2012); e-pub ahead of print 14 November 2012.
4. Relling, M.V., & Klein, T.E. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther. 89(3), 464-467 (2011).
5. Matimba, A. et al. Establishment of a biobank and pharmacogenetics database of African populations. Eur. J. Hum. Genet. 16, 780-783 (2008).
6. Chigutsa, E. et al. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob. Agents Chemother. 55, 4122-4127 (2011).
7. Nyakutira, C. et al. High prevalence of the CYP2B6 516G->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur. J. Clin. Pharmacol. 64, 357-365 (2008).
8. Nemaura, T., Nhachi, C., & Masimirembwa, C. Impact of gender, weight and CYP2B6 genotype on efavirenz exposure in patients on HIV/AIDS and TB treatment: implications for individualising therapy. Afr. J. Pharm. Pharmacol. 6, 2188-2193 (2012).
9. Masimirembwa, C., Persson, I., Bertilsson, L., Hasler, J. & Ingelman-Sundberg, M. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br. J. Clin. Pharmacol. 42, 713-719 (1996).
10. Daly, A.K. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms. Arch. Toxicol. 87, 407-420 (2013).